Retrospective study of anti-GD2 Immunotherapy

Relationship of Clinical Course with Prior Therapy in anti-GD2 Immunotherapy-Retrospective study - JN-GD2-23

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1050230140

Enrollment

120

Registered

2023-12-03

Start date

2024-02-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neuroblastoma Neuroblastoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Cases falling under (i) or (ii) (i) Cases with newly diagnosed neuroblastoma who was started GD2 immunotherapy between September 1, 2021 and December 31, 2022 within 1 year of transplantation (autologous or allogeneic) (ii) Cases with recurrent or relapsed neuroblastoma who was started GD2 immunotherapy between September 1, 2021 and December 31, 2022.

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
GD2 Immunotherapy Completion by Allogeneic Transplant History	—

Secondary

Measure	Time frame
Adverse Events of GD2 Immunotherapy Drug Dose Changes in GD2 Immunotherapy Event free survival	—

Contacts

Public ContactChika Nitani

Osaka City General Hospital

c-tanaka@med.osakacity-hp.or.jp+81-6-6929-1221

Outcome results